When your body has enough testosterone, the brain does not send the LH signal to your testicles. Therefore, you will not make any testosterone until your levels drop to below normal and the signal returns, stimulating production. Since you are getting testosterone from an outside source, your brain is most likely not sending that signal to your testicles. Over time, the old adage of “use it or lose it” comes into play and your testicles will shrink in size. The time is different for every man and the amount of “shrinkage” is different for every man. Fortunately, the HCG will quickly restore the size and function.
In previous studies of testicular biopsy tissue from healthy men, intratesticular testosterone (ITT) has been shown to be much higher than serum testosterone (T), suggesting that high ITT is needed relative to serum T for normal spermatogenesis in men. However, the quantitative relationship between ITT and spermatogenesis is not known. To begin to address this issue experimentally, we determined the dose-response relationship between human chorionic gonadotropin (hCG) and ITT to ascertain the minimum dose needed to maintain ITT in the normal range. Twenty-nine men with normal reproductive physiology were randomized to receive 200 mg T enanthate weekly in combination with either saline placebo or 125, 250, or 500 IU hCG every other day for 3 wk. ITT was assessed in testicular fluid obtained by percutaneous fine needle aspiration at baseline and at the end of treatment. Baseline serum T ( nmol/liter) was % of ITT (1174 nmol/liter). LH and FSH were profoundly suppressed to 5% and 3% of baseline, respectively, and ITT was suppressed by 94% (1234 to 72 nmol/liter) in the T enanthate/placebo group. ITT increased linearly with increasing hCG dose (P < ). Posttreatment ITT was 25% less than baseline in the 125 IU hCG group, 7% less than baseline in the 250 IU hCG group, and 26% greater than baseline in the 500 IU hCG group. These results demonstrate that relatively low dose hCG maintains ITT within the normal range in healthy men with gonadotropin suppression. Extensions of this study will allow determination of the ITT concentration threshold required to maintain spermatogenesis in man.
DISCLAIMER- NO PRESCRIPTION WILL BE PROVIDED UNLESS A CLINICAL NEED EXISTS BASED ON REQUIRED LAB WORK, PHYSICIAN CONSULTATION AND CURRENT MEDICAL HISTORY EITHER THROUGH PATIENT'S PERSONAL PHYSICIAN OR Pharmacy Rx Solutions PHYSICIAN. AGREEING TO LAB WORK DOES NOT AUTOMATICALLY EQUATE TO CLINICAL NECESSITY AND A PRESCRIPTION. No claim or opinion made by PharmacyRx Solutions is intended to be, or should be construed to be medical advice. Please consult with a healthcare professional before starting any therapeutic program.